Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 78

Cited In for PubMed (Select 9236948)

1.

Alzheimer's disease progression by geographical region in a clinical trial setting.

Henley DB, Dowsett SA, Chen YF, Liu-Seifert H, Grill JD, Doody RS, Aisen P, Raman R, Miller DS, Hake AM, Cummings J.

Alzheimers Res Ther. 2015 Jun 25;7(1):43. doi: 10.1186/s13195-015-0127-0. eCollection 2015.

2.

Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials.

Grill JD, Raman R, Ernstrom K, Aisen P, Dowsett SA, Chen YF, Liu-Seifert H, Hake AM, Miller DS, Doody RS, Henley DB, Cummings JL.

Alzheimers Res Ther. 2015 Jun 25;7(1):39. doi: 10.1186/s13195-015-0122-5. eCollection 2015.

3.

Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer's disease.

Doody RS, Raman R, Sperling RA, Seimers E, Sethuraman G, Mohs R, Farlow M, Iwatsubo T, Vellas B, Sun X, Ernstrom K, Thomas RG, Aisen PS; Alzheimer’s Disease Cooperative Study.

Alzheimers Res Ther. 2015 Jun 10;7(1):36. doi: 10.1186/s13195-015-0121-6. eCollection 2015.

4.

Effects of pioglitazone or exercise in older adults with mild cognitive impairment and insulin resistance: a pilot study.

Hildreth KL, Van Pelt RE, Moreau KL, Grigsby J, Hoth KF, Pelak V, Anderson CA, Parnes B, Kittelson J, Wolfe P, Nakamura T, Linnebur SA, Trujillo JM, Aquilante CL, Schwartz RS.

Dement Geriatr Cogn Dis Extra. 2015 Feb 20;5(1):51-63. doi: 10.1159/000371509. eCollection 2015 Jan-Apr.

5.

Anxiety symptoms in amnestic mild cognitive impairment are associated with medial temporal atrophy and predict conversion to Alzheimer disease.

Mah L, Binns MA, Steffens DC; Alzheimer's Disease Neuroimaging Initiative.

Am J Geriatr Psychiatry. 2015 May;23(5):466-76. doi: 10.1016/j.jagp.2014.10.005. Epub 2014 Oct 29.

PMID:
25500120
6.

Subsets of a large cognitive battery better power clinical trials on early stage Alzheimer's disease.

Xiong C, Weng H, Bennett DA, Boyle PA, Shah RC, Fague S, Hall CB, Lipton RB, Morris JC.

Neuroepidemiology. 2014;43(2):131-9. doi: 10.1159/000365733. Epub 2014 Nov 5.

PMID:
25376544
7.

Frontobasal gray matter loss is associated with the TREM2 p.R47H variant.

Luis EO, Ortega-Cubero S, Lamet I, Razquin C, Cruchaga C, Benitez BA, Lorenzo E, Irigoyen J; Alzheimer's Disease Neuroimaging Initiative (ADNI), Pastor MA, Pastor P.

Neurobiol Aging. 2014 Dec;35(12):2681-90. doi: 10.1016/j.neurobiolaging.2014.06.007. Epub 2014 Jun 17.

PMID:
25027412
8.

Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial.

Wade AG, Farmer M, Harari G, Fund N, Laudon M, Nir T, Frydman-Marom A, Zisapel N.

Clin Interv Aging. 2014 Jun 18;9:947-61. doi: 10.2147/CIA.S65625. eCollection 2014.

9.

Randomized controlled trials in frontotemporal dementia: cognitive and behavioral outcomes.

Miller JB, Banks SJ, Léger GC, Cummings JL.

Transl Neurodegener. 2014 Jun 5;3:12. doi: 10.1186/2047-9158-3-12. eCollection 2014. Review.

10.

Directed progression brain networks in Alzheimer's disease: properties and classification.

Friedman EJ, Young K, Asif D, Jutla I, Liang M, Wilson S, Landsberg AS, Schuff N; Alzheimer’s Disease Neuroimaging Initiative.

Brain Connect. 2014 Jun;4(5):384-93. doi: 10.1089/brain.2014.0235.

11.

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.

Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, Weiner M, Aisen PS; Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing; Alzheimer’s Disease Neuroimaging Initiative; Alzheimer’s Disease Cooperative Study.

JAMA Neurol. 2014 Aug;71(8):961-70. doi: 10.1001/jamaneurol.2014.803.

12.

Extension and refinement of the predictive value of different classes of markers in ADNI: four-year follow-up data.

Gomar JJ, Conejero-Goldberg C, Davies P, Goldberg TE; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2014 Nov;10(6):704-12. doi: 10.1016/j.jalz.2013.11.009. Epub 2014 Mar 6.

PMID:
24613706
13.

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014.

Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad B, Kivipelto M.

J Intern Med. 2014 Mar;275(3):251-83. doi: 10.1111/joim.12191. Review.

14.

Improved utilization of ADAS-cog assessment data through item response theory based pharmacometric modeling.

Ueckert S, Plan EL, Ito K, Karlsson MO, Corrigan B, Hooker AC; Alzheimer’s Disease Neuroimaging Initiative.

Pharm Res. 2014 Aug;31(8):2152-65. doi: 10.1007/s11095-014-1315-5. Epub 2014 Mar 5.

15.
16.

A systematic review of biomarkers for disease progression in Alzheimer's disease.

McGhee DJ, Ritchie CW, Thompson PA, Wright DE, Zajicek JP, Counsell CE.

PLoS One. 2014 Feb 18;9(2):e88854. doi: 10.1371/journal.pone.0088854. eCollection 2014. Review. Erratum in: PLoS One. 2014;9(5):e97960.

17.

A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design.

Guekht A, Skoog I, Korczyn AD, Zakharov V, Eeg M, Vigonius U.

Dement Geriatr Cogn Dis Extra. 2013 Dec 14;3(1):459-67. doi: 10.1159/000357122. eCollection 2013 Jan.

18.

Combining Multiple Markers to Improve the Longitudinal Rate of Progression-Application to Clinical Trials on the Early Stage of Alzheimer's Disease.

Xiong C, van Belle G, Chen K, Tian L, Luo J, Gao F, Yan Y, Chen L, Morris JC, Crane P.

Stat Biopharm Res. 2013 Jan 1;5(1). doi: 10.1080/19466315.2012.756662.

19.
20.

Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly.

Salmon DP, Ferris SH, Thomas RG, Sano M, Cummings JL, Sperling RA, Petersen RC, Aisen PS.

Neuropsychology. 2013 Jul;27(4):391-401. doi: 10.1037/a0032707.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk